8-K: ProMIS Neurosciences Receives Nasdaq Extension to Regain Bid Price Compliance

ProMIS Neurosciences Inc. has been granted an additional 180-calendar day period by Nasdaq, until December 29, 2025, to regain compliance with the minimum $1.00 bid price requirement.

Summary

• ProMIS Neurosciences Inc. (PMN) received a deficiency letter from Nasdaq on January 8, 2025, for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2).
• The initial compliance deadline was July 2, 2025.
• Nasdaq has granted the company an additional 180-calendar day compliance period, extending the deadline to December 29, 2025.
• This extension was granted because the company meets the continued listing requirement for stockholders' equity and all other initial listing standards for the Nasdaq Capital Market, with the exception of the Bid Price Rule.
• The company has confirmed its intention to cure the deficiency, including by potentially effecting a reverse stock split if necessary.
• The company's common shares continue to trade uninterrupted on the Nasdaq Capital Market under the symbol PMN.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While an extension was granted, the underlying issue of non-compliance with Nasdaq's bid price rule persists, and the risk of delisting remains. The need to consider a reverse stock split also indicates a challenging situation.

Positives

• Nasdaq granted an additional 180-calendar day compliance period, extending the deadline to December 29, 2025.
• The company meets the continued listing requirement for stockholders' equity and all other initial listing standards for the Nasdaq Capital Market, indicating underlying financial stability beyond the bid price issue.
• The company's common shares continue to trade uninterrupted on the Nasdaq Capital Market.

Negatives

• The company remains non-compliant with Nasdaq's minimum $1.00 bid price requirement.
• There is no assurance that the company will be able to regain compliance by the new deadline of December 29, 2025.
• Failure to regain compliance could lead to delisting from Nasdaq, which may negatively impact liquidity and investor confidence.
• The potential need for a reverse stock split could dilute existing shareholder value or be perceived negatively by the market.

Risks

• The company may not regain compliance with the Minimum Bid Price Rule by the Second Compliance Date (December 29, 2025).
• Nasdaq may not grant the company further relief from delisting if necessary.
• The company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary.
• If delisted, the company may appeal Nasdaq's determination, but there is no assurance such an appeal would be successful.
• The company may not be able to maintain its listing with Nasdaq.

Future Outlook

The company intends to actively monitor the closing bid price of its Common Shares and will consider available options to regain compliance with the Bid Price Rule, including potentially effecting a reverse stock split if necessary. There is no assurance that compliance will be regained by the December 29, 2025 deadline.

Management Comments

• The company intends to actively monitor the closing bid price of its Common Shares.
• The company will consider available options to regain compliance with the Bid Price Rule, including seeking to effect a reverse stock split, if necessary.

Industry Context

This announcement relates to a common regulatory challenge faced by smaller biotechnology and neuroscience companies listed on major exchanges like Nasdaq, where maintaining a minimum share price can be difficult due to market volatility, limited trading volume, or early-stage development without significant revenue. Companies in this sector often rely on capital markets for funding, making exchange listing crucial.

Stakeholder Impact

• Shareholders face potential dilution if a reverse stock split is implemented.
• Shareholders face the risk of reduced liquidity and investor confidence if the company is ultimately delisted from Nasdaq.

Next Steps

• Actively monitor the closing bid price of Common Shares.
• Consider available options to regain compliance with the Bid Price Rule, including a reverse stock split if necessary.
• If compliance is not regained by December 29, 2025, the company may appeal Nasdaq's delisting determination to a hearings panel.

Key Dates

Recommendation

Keywords

Nasdaq, delisting, bid price rule, compliance, reverse stock split, PROMIS Neurosciences, PMN, stock market, listing standards, regulatory filing